{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:20:37Z","timestamp":1790659237826,"version":"4.1.0"},"reference-count":23,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi & Co., Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The long-term safety and effectiveness of metreleptin in patients with lipodystrophy were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted postmarketing surveillance of all patients administered metreleptin at least once from July 2013 at its launch through July 2021 in Japan. Data were collected through July 2022. The safety analysis set included all patients with Case Report Forms (CRFs) retrieved, including those who transitioned from premarketing clinical trials and those who newly initiated metreleptin after its launch. Only the latter cases were eligible for the effectiveness analysis set. Effectiveness was evaluated by changes in glycated hemoglobin (HbA1c) and triglyceride levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>CRFs were collected from 48 patients. Thirty-six were new cases, and 12 were transitioned cases. Twenty-six types of adverse drug reactions (ADRs) were reported in 15 patients. The most reported ADRs were \u201cdecreased appetite\u201d and \u201cneutralizing antibodies positive,\u201d reported in 3 patients each. However, there were no safety concerns overall. Mean levels of HbA1c and triglycerides decreased at 2 or 4 months of treatment. Values thereafter remained stable for up to 7 years for HbA1c and triglycerides. Mean levels of HbA1c and triglycerides improved after 1, 2, and 3 years, although the change was not as great in partial lipodystrophy patients as in generalized lipodystrophy patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Metreleptin treatment was generally well tolerated in patients with generalized and partial lipodystrophy and lowered HbA1c and triglycerides in those with generalized lipodystrophy. This surveillance demonstrated for the first time the long-term safety in the real world and the effectiveness in patients who used the medication correctly.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/jendso\/bvaf216","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T12:59:49Z","timestamp":1766149189000},"source":"Crossref","is-referenced-by-count":2,"title":["Postmarketing Surveillance of the Safety and Effectiveness of Metreleptin in Patients with Lipodystrophy in Japan"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-0617","authenticated-orcid":false,"given":"Ken","family":"Ebihara","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Jichi Medical University , Shimotsuke 329-0498 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Hata","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department, Shionogi & Co., Ltd. , Osaka 530-0011 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Medical Affairs Department, Shionogi & Co., Ltd. , Osaka 530-0011 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Miyano","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Division, Shionogi Business Partner Co., Ltd. , Osaka 541-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"issue":"12","key":"2026012710511092700_bvaf216-B1","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2026012710511092700_bvaf216-B2","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1210\/jc.2018-02730","article-title":"Comorbidities and survival in patients with lipodystrophy: an international chart review study","volume":"104","author":"Akinci","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026012710511092700_bvaf216-B3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13023-023-02714-5","article-title":"The metreleptin effectiveness and safety registry (MEASuRE): concept, design and challenges","volume":"18","author":"Haymond","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2026012710511092700_bvaf216-B4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2147\/DMSO.S130810","article-title":"Estimating the prevalence of generalized and partial lipodystrophy: findings and challenges","volume":"10","author":"Chiquette","year":"2017","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2026012710511092700_bvaf216-B5","first-page":"15","article-title":"Current state of lipodystrophy syndromes in Japan","volume":"17","author":"Ebihara","year":"2011","journal-title":"J Japan Society for the Study of Obesity"},{"issue":"9","key":"2026012710511092700_bvaf216-B6","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11892-022-01485-w","article-title":"Lipodystrophy for the diabetologist\u2013what to look for","volume":"22","author":"Patni","year":"2022","journal-title":"Curr Diab Rep"},{"issue":"8","key":"2026012710511092700_bvaf216-B7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"issue":"6505","key":"2026012710511092700_bvaf216-B8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"issue":"2","key":"2026012710511092700_bvaf216-B9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/0003-4819-152-2-201001190-00008","article-title":"Narrative review: the role of leptin in human physiology: emerging clinical applications","volume":"152","author":"Kelesidis","year":"2010","journal-title":"Ann Intern Med"},{"issue":"5","key":"2026012710511092700_bvaf216-B10","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026012710511092700_bvaf216-B11","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1507\/endocrj.EJ21-0110","article-title":"Practice guideline for lipodystrophy syndromes-clinically important diseases of the Japan Endocrine Society (JES)","volume":"68","author":"Tanaka","year":"2021","journal-title":"Endocr J"},{"issue":"1","key":"2026012710511092700_bvaf216-B12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2026012710511092700_bvaf216-B13","doi-asserted-by":"publisher","DOI":"10.17632\/n6bdf8t784.1","article-title":"Data from: Post-marketing surveillance of the safety and effectiveness of metreleptin in patients with lipodystrophy in Japan","author":"Ebihara","journal-title":"Mendeley Data"},{"issue":"2","key":"2026012710511092700_bvaf216-B14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2006-1546","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy","volume":"92","author":"Ebihara","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026012710511092700_bvaf216-B15","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.2337\/dc13-2040","article-title":"Effects of leptin replacement therapy on pancreatic \u03b2-cell function in patients with lipodystrophy","volume":"37","author":"Muniyappa","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"2026012710511092700_bvaf216-B16","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"issue":"6","key":"2026012710511092700_bvaf216-B17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4158\/EP11229.OR","article-title":"Clinical effects of long-term metreleptin treatment in patients with lipodystrophy","volume":"17","author":"Chan","year":"2011","journal-title":"Endocr Pract"},{"issue":"3","key":"2026012710511092700_bvaf216-B18","first-page":"659","article-title":"Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program","volume":"7","author":"Ajluni","year":"2016","journal-title":"J Diabetes Metab"},{"issue":"1","key":"2026012710511092700_bvaf216-B19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/10428194.2015.1040015","article-title":"Lymphoma in acquired generalized lipodystrophy","volume":"57","author":"Brown","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"2026012710511092700_bvaf216-B20","author":"Chiesi USA, Inc"},{"issue":"6","key":"2026012710511092700_bvaf216-B21","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJM200408053510623","article-title":"Long-term leptin-replacement therapy for lipoatrophic diabetes","volume":"351","author":"Ebihara","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"2026012710511092700_bvaf216-B22","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s12020-018-1589-1","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy","volume":"60","author":"Brown","year":"2018","journal-title":"Endocrine"},{"issue":"8","key":"2026012710511092700_bvaf216-B23","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/dom.14726","article-title":"Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: real-life experience from a national reference network","volume":"24","author":"Mosbah","year":"2022","journal-title":"Diabetes Obes Metab"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf216\/66108787\/bvaf216.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/2\/bvaf216\/66108787\/bvaf216.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/2\/bvaf216\/66108787\/bvaf216.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:51:20Z","timestamp":1769529080000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf216\/8402160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf216","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,12,23]]},"article-number":"bvaf216"}}